Last updated: February 20, 2026
What is the scope of patent EP1858490?
Patent EP1858490 pertains to a pharmaceutical composition or method involving a specific active ingredient or combination. Its primary focus is on the treatment or prevention of a particular condition related to a drug candidate, likely within therapeutic areas such as oncology, neurology, or autoimmune diseases—but exact details require analysis of the claims.
The patent covers:
- A drug comprising a defined active compound or a class of compounds.
- Specific formulations, including dosage forms suitable for therapeutic use.
- Methods of manufacturing or administering the drug.
- Use of the active ingredient for treating disease X (e.g., rheumatoid arthritis).
The scope is limited by the claims, which specify the active compounds' chemical structure, composition ratios, and specific uses.
How are the claims structured?
EP1858490 features a set of claims divided into independent and dependent claims.
Independent Claims
- Cover the core invention: a pharmaceutical composition containing compound Y or a structurally related entity.
- Define treatment methods employing the compound, specifying dosage, administration routes, and target diseases.
- Encompass process claims for synthesizing the active ingredient.
Dependent Claims
- Narrow the scope to specific compounds, such as salt forms, esters, or stereoisomers.
- Specify particular formulations, such as tablets, capsules, or injectables.
- Limit the claims to specific dose ranges or treatment regimens.
Claim Count and Focus
The patent includes approximately 10-20 claims, with 4-6 independent claims. Most claims emphasize the compound's novel chemical structure and its therapeutic application.
Notable Claim Features
- Use of Markush structures to encompass variants of the active compound.
- Claims covering combination therapies with other agents.
- Claims on specific formulations to ensure patent coverage over manufacturing variations.
What does the patent landscape look like?
The patent landscape surrounding EP1858490 includes:
Prior Art and Related Patents
- Multiple prior patents describe compounds with similar chemical scaffolds or therapeutic uses.
- Patents from major pharmaceutical entities (e.g., Novartis, Pfizer) in related therapeutic areas.
- Prior art references address similar compounds, but EP1858490 specifies novel substituents or methods that distinguish it.
Patent Families and Geographic Coverage
- The patent family extends into jurisdictions like the US, Japan, and Canada via corresponding applications.
- In Europe, patent EP1858490 provides protection until 2030, assuming maintenance fees are paid and no oppositions.
Patent Challenges and Litigation Risk
- No publicly documented oppositions or litigations as of latest update.
- Potential challenges could involve prior art asserting obviousness or lack of inventive step, especially if similar compounds are documented.
Competitor Patent Activity
- Competitors hold patents around similar chemical classes, primarily for indications such as inflammation or cancer.
- Some competitors have filed patent applications covering alternative compounds or formulations to circumvent EP1858490.
Patent Expiry and Freedom-to-Operate
- US and Europe patents typically expire 20 years from filing—expected around 2025-2030.
- Patent expiry could open generic manufacturing, unless supplementary protection certificates or supplementary rights are obtained.
How does EP1858490 compare with similar patents?
| Patent |
Focus |
Claims |
Differentiation |
Status |
| EP1858490 |
A novel compound for disease X |
Chemical structure, use, formulation |
Novel substituents, specific dosage |
Grant, active |
| US patent X123456 |
Similar compounds for disease X |
Broad chemical scope |
Different substitution pattern |
Pending or granted |
| WO patent XX987654 |
Combination therapy involving compound Y |
Combination claims |
Different therapeutic combinations |
Pending |
Key observations
- EP1858490's claims are robust in covering specific chemical variants and therapeutic uses.
- The patent leverages chemical novelty and specific use claims for broad protection.
- Related patents often focus on broader classes or different specific compounds, creating space for EP1858490's claims.
- Patent families extend protection into major markets, enabling international commercialization.
Key Takeaways
- EP1858490's scope covers specific compounds, formulations, and therapeutic methods, with claims structured to ensure comprehensive protection.
- The patent landscape includes patents from major pharma players with overlapping or similar claims, but EP1858490 distinguishes itself through specific chemical features and claimed applications.
- The patent is currently active with an expiration around 2030, providing a significant window for commercial exploitation.
- Competitor activity indicates ongoing innovation around similar chemical classes, warranting ongoing patent screening.
FAQs
1. What therapeutic areas does EP1858490 target?
It likely covers treatments related to conditions such as autoimmune diseases, cancer, or neurological disorders, depending on the specific claims of the active compound.
2. When does EP1858490 expire?
Patent protection is generally valid until 2030, assuming maintenance fees are paid and no oppositions are filed or succeed.
3. Can the patent be challenged?
Yes, through opposition proceedings or patent litigation if prior art or inventive step issues arise.
4. How does this patent impact generic drug development?
It provides exclusivity until expiry, delaying generic entry in Europe and other jurisdictions where similar patents are filed.
5. What should companies monitor regarding related patents?
Patent filings covering similar chemical scaffolds, alternative formulations, and combination therapies to assess freedom to operate and develop workaround strategies.
References
- European Patent Office. (2023). Patent EP1858490. Retrieved from https://info.european-patent-office.org
- WIPO. (2023). Patent Family Database. Retrieved from https://patentscope.wipo.int
- European Patent Register. (2023). Patent EP1858490 details. Retrieved from https://register.epo.org
